AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
ANAPTYSBIO, INC amendment reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each beneficially own 55,303 shares of common stock, representing 0.2% of the class. The ownership figures are stated as of the close of business on March 31, 2026.
The filing explains Point72 Asset Management holds investment and voting power over the shares on behalf of an investment fund, Point72 Capital Advisors Inc. is the general partner, and Mr. Cohen controls both entities. The statement clarifies these reporting persons directly own no shares.
AnaptysBio, Inc. Schedule 13G disclosure states that Sirenia Capital Management and Alex Silverstein report shared dispositive power over 1,920,402 shares of AnaptysBio common stock, representing 6.7% of the class. The filing bases the percentage on 28,748,255 shares outstanding as of February 27, 2026. The report covers holdings by the Sirenia Fund and Sirenia Account; a Joint Filing Agreement is included as Exhibit 99.1.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
ANAPTYSBIO director Owen Hughes received a grant of restricted stock units (RSUs). On May 11, 2026, he was awarded 11,250 RSUs, each representing a contingent right to receive one share of common stock for no cash payment upon settlement.
One third of these RSUs will vest on May 11, 2027, with the remaining two thirds vesting in equal annual installments, provided he continues to serve the company on each vesting date. After this grant, his reported RSU holdings from this award total 11,250 units held directly.
ANAPTYSBIO, INC director Hughes Owen filed an initial insider ownership report on Form 3. This filing establishes his status as a company insider under SEC rules. The submission does not list any buy, sell, or other reportable transactions and shows no derivative positions.
Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.
AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.
The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.
ANAPTYSBIO, INC executive Christopher M. Murphy, the company’s Chief Financial Officer, has filed an initial Form 3 reporting his beneficial ownership status. In this filing, he does not report any transactions or existing holdings, indicating no reportable equity position or activity at the time of this statement.
AnaptysBio reports a royalty-focused Q1 2026 with a wider loss as it prepares for a spin-off of its drug development business. Collaboration revenue was $25.6 million, entirely from non-cash royalties on GSK’s Jemperli and Zejula. Research and development expense fell to $34.0 million as late-stage programs wound down, while general and administrative costs rose to $26.2 million, driven by legal spending and separation-related costs.
The company recorded a net loss of $52.9 million and significant non-cash interest expense of $20.9 million on royalty monetization liabilities tied to Jemperli and Zejula. Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. On April 20, 2026, after quarter-end, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, retaining a royalty-management focus around Jemperli and its imsidolimab collaboration with Vanda.
AnaptysBio, Inc. reported first-quarter 2026 results and highlighted its transition to a royalty-focused business following the spin-off of First Tracks Biotherapeutics. The company now manages financial collaborations for Jemperli with GSK and imsidolimab with Vanda, targeting an EBIT margin greater than 95% with streamlined operations.
Collaboration revenue was $25.6 million for the quarter, down from $27.8 million a year earlier, as prior Vanda license revenue rolled off but Jemperli royalties grew 44% from $17.2 million to $24.7 million. AnaptysBio posted a net loss of $52.9 million, or $1.84 per share, compared with a $39.3 million loss in the prior-year period.
Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, versus $311.6 million at year-end 2025. The company announced a $100 million stock repurchase plan expiring December 31, 2026, and continues to carry a liability of $263.7 million related to the sale of future Jemperli royalties. Management reiterated expectations of more than $390 million in annualized Jemperli royalties payable to AnaptysBio as early as 2029 based on GSK’s peak sales guidance, and noted a December 12, 2026 FDA target action date for imsidolimab in generalized pustular psoriasis.
AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.
If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.